Insulin detemir is a long-acting human insulin analogue for maintaining the basal level of insulin, Novo Nordisk markets it under which trade name?
226e74d7add12fcccc07c9917e4785c9
Insulin detemir Insulin detemir is a long-acting human insulin analogue for maintaining the basal level of insulin. Novo Nordisk markets it under the trade name Levemir. It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
b2c4ca84b401d89573fd61935ccbe295
Novo Nordisk Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (75%) of its voting shares.
2cc5d4aa67f3851a6391ddde6716de69
Exenatide Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. It is manufactured by Amylin Pharmaceuticals and commercialized by AstraZeneca.
09fae579bf7980717f567e3838eb324d
Metabolic Technologies, Inc. Metabolic Technologies, Inc is an American life sciences company that sells dietary supplements and analytical services. Metabolic Technologies is headquartered in Ames, Iowa.
f80f6343de2f08a0d64d56329d2ac16f
Navilyst Medical Navilyst Medical, Inc. is a manufacturer of vascular medical equipment, including catheters, ports, and embolization devices. The company name is based on the root "navi" (as in "navigation") and the suffix "lyst" (as in "catalyst").
69a69233c3508ead2568aaaa7ac92f8e
Ranimustine Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera.
e8aa2f187d35b652020eae366fdd34b8
Anamorelin Anamorelin (INN) (developmental code names ONO-7643, RC-1291, ST-1291), also known as anamorelin hydrochloride (USAN, JAN), is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Healthcare SA for the treatment of cancer cachexia and anorexia.
b42d6b88eceb54ce12e9ac4abd8cd4e4
Catridecacog Catridecacog (brand name Tretten in the US and NovoThirteen in Europe) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
58098324b547ceb6b144b80d3bab87c0
Norethisterone Norethisterone (NET), also known as norethindrone, is a medication that is used in combination with estrogen or alone in hormonal contraceptives, hormone replacement therapy, and in the treatment of gynecological disorders. It is a synthetic progestogen (or a progestin) of the 19-nortestosterone group and has similar effects to those of natural progesterone, including suppression of gonadotropins, ovulation inhibition, and endometrial transformation. In addition to its progestogenic activity, NET also has weak androgenic and estrogenic effects at high dosages. In addition to NET itself, several prodrugs of NET, such as norethisterone acetate (NETA), norethisterone enanthate (NETE), and others, have been marketed and have similar effects and uses.
84dde5ac5051be76757d6c2c0989d352
1-Androsterone 1-Androsterone (also known as 1-andro, 1-dehydroepiandrosterone, 1-DHEA, δ-epiandrosterone, or 5α-androst-1-en-3β-ol-17-one) is a synthetic, orally active anabolic-androgenic steroid (AAS). It is an androgen prohormone of 1-testosterone (dihydroboldenone), 1-androstenedione, and other 1-dehydrogenated androstanes. The drug has been sold on the Internet as a designer steroid and "dietary supplement". It is a positional isomer of dehydroepiandrosterone (DHEA; 5-dehydroepiandrosterone).
5657728b0fa901793aacf064a1d8a58f
Semaglutide Semaglutide (USAN) is a pharmaceutical drug in development by Novo Nordisk for the treatment of type 2 diabetes.
a00dbfff9eb93537dee5daecbfedc338
Lixisenatide Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II.
9821369370dbafd086ad0dc81dd6c111
Human placental lactogen Human placental lactogen (hPL), also called human chorionic somatomammotropin (HCS), is a polypeptide placental hormone, the human form of placental lactogen (chorionic somatomammotropin). Its structure and function are similar to those of human growth hormone. It modifies the metabolic state of the mother during pregnancy to facilitate the energy supply of the fetus. hPL has anti-insulin properties. hPL is a hormone secreted by the syncytiotrophoblast during pregnancy. Like human growth hormone, hPL is encoded by genes on chromosome 17q22-24. It was identified in 1963.
57a0134078ca31c53da8f8cb56c4f9bc
Formestane Formestane (trade name Lentaron), also known as 4-hydroxyandrost-4-ene-3,17-dione, is a type I, steroidal, selective aromatase inhibitor. It is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and is instead available only as an intramuscular depot injection. Because of this, it is no longer popular as many orally active aromatase inhibitors have been identified and introduced. Formestane is an analogue of androstenedione.
0d7cbe1287b380a8cc43b0abfdeeaf8e
Mitratapide Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids. Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.
7a789e2750b771ff8fcb53d20b035caf
Anacetrapib Anacetrapib (USAN, pINN; codenamed MK-0859, Merck) is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.
f17568fd90b7ff9cf072780322819846
Broparestrol Broparestrol (INN) (brand names Acnestrol, Longestrol; former developmental code name LN-107), also known as α-bromo-α,β-diphenyl-β-p-ethylphenylethylene (BDPE), is a synthetic, nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is or was used in Europe as a dermatological agent and for the treatment of breast cancer. The drug is described as slightly estrogenic and potently antiestrogenic, and inhibits mammary gland development and suppresses prolactin levels in animals. It is structurally related to clomifene and diethylstilbestrol.
7ffcdd56072f1e872052a00b1bc3a8fb
Lavoltidine Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
b14f1c17f14fdf9472b2cf698cf26b48
Silence Therapeutics Silence Therapeutics (AIM:SLN) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters at 1 Lyric Square, London.
30f0e807b6599145cd97725d4f53b3a9
Phenformin Phenformin is an antidiabetic drug from the biguanide class. It was marketed as DBI by Ciba-Geigy, but was withdrawn from most markets in the late 1970s due to a high risk of lactic acidosis, which was fatal in 50% of cases.
232e084016abf366d66bb7588b667197
Nalfurafine Nalfurafine (INN, USAN) (brand name Remitch; former developmental code names TRK-820, AC-820, MT-9938) is an antipruritic (anti-itch drug) that is marketed in Japan for the treatment of uremic pruritus in individuals with chronic kidney disease undergoing hemodialysis. It acts as a potent, selective, centrally-penetrant κ-opioid receptor (KOR) agonist, and is the first and currently the only selective KOR agonist to have been approved for clinical use. It has also been dubiously referred to as the "first non-narcotic opioid drug" in history.
db473bb7889942b8b0e77e38c18c6bc8
Empagliflozin Empagliflozin (trade name Jardiance) is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company.